Kalpit Patel
Stock Analyst at B. Riley Securities
(1.08)
# 3,587
Out of 4,835 analysts
54
Total ratings
30%
Success rate
-10.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $8.10 | +72.84% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $19.44 | +90.33% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $19.84 | +21.00% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.27 | +175.59% | 3 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $7.59 | +18.58% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $4.48 | +123.21% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.42 | +392.96% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $7.34 | +444.96% | 2 | Sep 20, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Neutral | $31 → $36 | $30.25 | +19.01% | 2 | Jul 9, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $0.30 | +890.10% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $12.94 | +54.56% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $2.92 | +927.40% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $6.97 | -13.92% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $9.05 | +297.79% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $3 | $0.13 | +2,231.00% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.11 | +1,521.62% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.03 | +146.91% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $7.54 | +1,226.26% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $7.85 | +855.41% | 2 | Sep 3, 2021 |
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $8.10
Upside: +72.84%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $19.44
Upside: +90.33%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $19.84
Upside: +21.00%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.27
Upside: +175.59%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $7.59
Upside: +18.58%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.48
Upside: +123.21%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.42
Upside: +392.96%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $7.34
Upside: +444.96%
Kymera Therapeutics
Jul 9, 2024
Maintains: Neutral
Price Target: $31 → $36
Current: $30.25
Upside: +19.01%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.30
Upside: +890.10%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $12.94
Upside: +54.56%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $2.92
Upside: +927.40%
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $6.97
Upside: -13.92%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $9.05
Upside: +297.79%
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $0.13
Upside: +2,231.00%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.11
Upside: +1,521.62%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $2.03
Upside: +146.91%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $7.54
Upside: +1,226.26%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $7.85
Upside: +855.41%